Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study to Evaluate the Safety and Effectiveness of Topiramate Compared to Placebo in the Treatment of Patients With Bipolar I Disorder

This study has been completed.
Sponsor:
Information provided by:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov Identifier:
NCT00035802
First received: May 6, 2002
Last updated: June 23, 2011
Last verified: June 2011
  Purpose

The purpose of this study is to determine the safety and efficacy of topiramate in adolescents with manic or mixed episodes of Bipolar I Disorder.


Condition Intervention Phase
Bipolar Disorder
Affective Disorders, Psychotic
Mood Disorders
Mental Disorders
Drug: Topiramate
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Multicenter, Placebo-Controlled 4-Week Study of the Safety and Efficacy of Topiramate in Adolescents With Acute Manic or Mixed Episodes of Bipolar I Disorder, With an Optional 6-Month Open-Label Extension

Resource links provided by NLM:


Further study details as provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:

Primary Outcome Measures:
  • Change from baseline in total Young Mania Rating Scale (YMRS) score [ Time Frame: Baseline to Day 28 (or last available observation prior to Day 28). ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change from baseline in Clinical Global Impression Scale (CGI-S) score [ Time Frame: Baseline to Day 28 (or last available observation prior to Day 28). ] [ Designated as safety issue: No ]
  • Change from baseline in Children's Global Assessment Scale (C-GAS) score [ Time Frame: Baseline to Day 28 (or last available observation prior to Day 28). ] [ Designated as safety issue: No ]
  • The number of patients continuing to meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for manic or mixed episodes of Bipolar I Disorder [ Time Frame: Day 28 (or last available observation prior to Day 28) ] [ Designated as safety issue: No ]

Enrollment: 13
Study Start Date: January 2002
Study Completion Date: April 2002
Arms Assigned Interventions
Experimental: 001

Topiramate Double-blind period: Up to 400 mg/day (two 100-mg tablets twice a day) for 28 days.

OL period: Up to 600 mg/day (three 100-mg tablets twice a day) for at least 6 months.

Drug: Topiramate

Double-blind period: Up to 400 mg/day (two 100-mg tablets twice a day) for 28 days.

OL period: Up to 600 mg/day (three 100-mg tablets twice a day) for at least 6 months.

Placebo Comparator: 002
Placebo Double-blind period: Equal number of matching placebo tablets for each of the topiramate tablet strengths twice a day for 28 days.
Drug: Placebo
Double-blind period: Equal number of matching placebo tablets for each of the topiramate tablet strengths twice a day for 28 days.

Detailed Description:

This is a 4-week study to evaluate the safety and effectiveness of topiramate compared to placebo in the treatment of Bipolar I Disorder with an optional 6-month open-label (OL) extension for qualified patients following completion of the study. On Days 1-28 patients will receive placebo or topiramate 2x/day by mouth except for the 1st and last doses which will be a single evening dose and a single morning dose, respectively. Study drug will be titrated in 100-mg increments to 400 mg/day and patients maintained on a stable dose through Day 28. During the OL extension phase, topiramate will be titrated over 5 days to 200 mg/day. After Day 7, topiramate may be tapered down to 100 mg/day or up to 600 mg/day, as clinically indicated.

  Eligibility

Ages Eligible for Study:   13 Years to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • DSM-IV diagnosis of Bipolar I Disorder (confirmed by the Kiddie-Schedule for Affective Disorders and Schizophrenia-Present and Lifetime version [K-SADS-P/L])
  • YMRS score greater than or equal to 20
  • General good health as determined by medical history, physical examination, and laboratory evaluations
  • Ability to swallow tablets
  • Patient's parent or guardian must be fully capable of monitoring the patient's disease process and compliance to treatment
  • Parent(s) or legal guardian(s) must read and sign the informed consent form after the nature of the study has been fully explained and assent must be obtained from patients

Exclusion Criteria:

  • DSM-IV Axis I disorder diagnoses of autistic disorder, schizophrenia, schizoaffective disorder, or other psychotic disorders not otherwise specified (NOS)
  • DSM-IV diagnosis of alcohol or substance dependence, with the exception of nicotine or caffeine dependence, within the 3 months prior to baseline. Acute or intermittent substance abuse prior to screening will not be exclusionary, depending upon the clinical judgment of the investigator
  • Chronic antidepressant treatment within 4 weeks of randomization (5 weeks for fluoxetine), use of psychostimulants in the 7 days prior to baseline, use of any other psychotropic medications within 3 days or 5 half-lives, whichever is less, prior to baseline, or requirement for treatment with other psychotropic drugs on an ongoing basis
  • Weight less than 33 kg or current or past history of anorexia nervosa
  • Serious or unstable medical or neurological conditions
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00035802

Sponsors and Collaborators
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Investigators
Study Director: Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
  More Information

No publications provided

Responsible Party: SR DIRECTOR CLINICAL LEADER, Johnson & Johnson Pharmaceutical Research and Development, L.L.C.
ClinicalTrials.gov Identifier: NCT00035802     History of Changes
Other Study ID Numbers: CR016867, TOPMAT-PDMD-009
Study First Received: May 6, 2002
Last Updated: June 23, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:
Bipolar
Mania
Pediatric
Children
Adolescent
Topiramate
Anticonvulsants
Central Nervous System Agents
Protective Agents
Neuroprotectiive Agents

Additional relevant MeSH terms:
Affective Disorders, Psychotic
Bipolar Disorder
Disease
Mental Disorders
Mood Disorders
Psychotic Disorders
Pathologic Processes
Schizophrenia and Disorders with Psychotic Features
Topiramate
Anti-Obesity Agents
Anticonvulsants
Central Nervous System Agents
Neuroprotective Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 24, 2014